291 related articles for article (PubMed ID: 8674154)
1. A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis.
Harman GS; Omura GA; Ryan K; Hainsworth JD; Cramer MB; Hahne WF
Cancer Chemother Pharmacol; 1996; 38(4):323-8. PubMed ID: 8674154
[TBL] [Abstract][Full Text] [Related]
2. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.
Audhuy B; Cappelaere P; Martin M; Cervantes A; Fabbro M; Rivière A; Khayat D; Bleiberg H; Faraldi M; Claverie N; Aranda E; Auclerc G; Audhuy B; Benhammouda A; Bleiberg H; Cals L; Cappelaere P; Cattan A; Cervantes A; Chevallier B; Conroy T; Cupissol D; De Grève J; Diaz-Rubio E; Seitz JF
Eur J Cancer; 1996 May; 32A(5):807-13. PubMed ID: 9081358
[TBL] [Abstract][Full Text] [Related]
3. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
Hesketh P; Navari R; Grote T; Gralla R; Hainsworth J; Kris M; Anthony L; Khojasteh A; Tapazoglou E; Benedict C; Hahne W
J Clin Oncol; 1996 Aug; 14(8):2242-9. PubMed ID: 8708713
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy.
Chevallier B; Cappelaere P; Splinter T; Fabbro M; Wendling JL; Cals L; Catimel G; Giovannini M; Khayat D; Bastit P; Claverie N
Support Care Cancer; 1997 Jan; 5(1):22-30. PubMed ID: 9010986
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group.
Rubenstein EB; Gralla RJ; Hainsworth JD; Hesketh PJ; Grote TH; Modiano MR; Khojasteh A; Kalman LA; Benedict CR; Hahne WF
Cancer; 1997 Mar; 79(6):1216-24. PubMed ID: 9070501
[TBL] [Abstract][Full Text] [Related]
6. Granisetron vs dolasetron for acute chemotherapy-induced nausea and vomiting (CINV) in high and moderately high emetogenic chemotherapy: an open-label pilot study.
Tan M; Xu R; Seth R
Curr Med Res Opin; 2004 Jun; 20(6):879-82. PubMed ID: 15200746
[TBL] [Abstract][Full Text] [Related]
7. Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy.
Yeilding A; Bertoli L; Eisenberg P; Plezia P; Modiano MR; Alberts DS; Khojasteh A; Cramer MB; Hahne WF
Am J Clin Oncol; 1996 Dec; 19(6):619-23. PubMed ID: 8931684
[TBL] [Abstract][Full Text] [Related]
8. Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral Dolasetron Dose Response Study Group.
Grote TH; Pineda LF; Figlin RA; Pendergrass KB; Hesketh PJ; Karlan BY; Reeves JA; Porter LL; Benedict CR; Hahne WF
Cancer J Sci Am; 1997; 3(1):45-51. PubMed ID: 9072308
[TBL] [Abstract][Full Text] [Related]
9. Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide.
Hesketh PJ; Gandara DR; Hesketh AM; Facada A; Perez EA; Webber LM; Martin LA; Cramer MB; Hahne WF
Support Care Cancer; 1996 Mar; 4(2):141-6. PubMed ID: 8673351
[TBL] [Abstract][Full Text] [Related]
10. Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting. Pooled analysis of 14 clinical trials.
Whitmore JB; Kris MG; Hesketh PJ; Grote TH; DuBois DM; Cramer MB; Hahne WF
Support Care Cancer; 1998 Sep; 6(5):473-8. PubMed ID: 9773466
[TBL] [Abstract][Full Text] [Related]
11. A double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomiting.
Fauser AA; Pizzocaro G; Schueller J; Khayat D; Wilkinson P
Support Care Cancer; 2000 Jan; 8(1):49-54. PubMed ID: 10650898
[TBL] [Abstract][Full Text] [Related]
12. Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin.
Kris MG; Grunberg SM; Gralla RJ; Baltzer L; Zaretsky SA; Lifsey D; Tyson LB; Schmidt L; Hahne WF
J Clin Oncol; 1994 May; 12(5):1045-9. PubMed ID: 8164028
[TBL] [Abstract][Full Text] [Related]
13. [Prophylaxis of nausea and vomiting after thyroid surgery: comparison of oral and intravenous dolasetron with intravenous droperidol and placebo].
Danner K; Becker HG; Best B; Madler C
Anasthesiol Intensivmed Notfallmed Schmerzther; 2001 Jul; 36(7):425-30. PubMed ID: 11496617
[TBL] [Abstract][Full Text] [Related]
14. Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone.
Kris MG; Pendergrass KB; Navari RM; Grote TH; Nelson AM; Thomas V; Ferguson BB; Allman DS; Pizzo BA; Baker TW; Fernando IJ; Chernoff SB
J Clin Oncol; 1997 May; 15(5):2135-8. PubMed ID: 9164228
[TBL] [Abstract][Full Text] [Related]
15. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
16. A double-blind, randomized study of two different dosage regimens of intravenous dolasetron in patients receiving high-dose cisplatin chemotherapy.
Kasimis BS; Tapazoglou E; Schulman P; Stewart WH; Hahne WF; Cramer MB
Cancer Invest; 1997; 15(4):304-10. PubMed ID: 9246150
[TBL] [Abstract][Full Text] [Related]
17. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
Sorbe BG
Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
[TBL] [Abstract][Full Text] [Related]
18. Intravenous dolasetron mesilate ameliorates postoperative nausea and vomiting.
Diemunsch P; Leeser J; Feiss P; D'Hollander A; Bradburn BG; Paxton D; Whitmore J; Panouillot P; Navé S; Brown RA; Hahne WF
Can J Anaesth; 1997 Feb; 44(2):173-81. PubMed ID: 9043731
[TBL] [Abstract][Full Text] [Related]
19. Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy.
Coppes MJ; Lau R; Ingram LC; Wiernikowski JT; Grant R; Howard DR; Perrotta M; Barr R; Dempsey E; Greenberg ML; Leclerc JM
Med Pediatr Oncol; 1999 Aug; 33(2):99-105. PubMed ID: 10398184
[TBL] [Abstract][Full Text] [Related]
20. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
Eisenberg P; Figueroa-Vadillo J; Zamora R; Charu V; Hajdenberg J; Cartmell A; Macciocchi A; Grunberg S;
Cancer; 2003 Dec; 98(11):2473-82. PubMed ID: 14635083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]